Table 3.

Clinical Manifestation according to Histology.

	Adeno	Squamous	p value
No. of patients	44	40
RECIST after CCRT, n (%)
PR or CR	33 (75.0)	26 (65.0)	0.348
PD	2 (4.5)	3 (7.5)	0.665
Durvalumab treatment, n (%)	39 (88.6)	33 (82.5)	0.537
Last radiation to durvalumab treatment
<14 days, n (%)	25 (64.1)	22 (66.7)	1
Administrated for one year	23 (59.0)	11 (33.3)	<0.05
Discontinuation due to causes other than PD	6 (15.3)	10 (30.3)	0.160
PD in term of durvalumab treatment	10 (25.6)	12 (36.4)	0.468
Total of PD, n (%)	22 (50.0)	30 (75.0)	<0.05
BSC after 1st line	1 (4.5)	11 (36.7)	<0.01

RECIST: response evaluation criteria in solid tumor, CCRT: concurrent chemoradiation therapy, PR: partial response, CR: complete response, PD: progressive disease, BSC: best supportive care